Hubei Goto Biopharm Co.,Ltd. (SHE:300966)

Market Cap	3.07B +65.7%
Revenue (ttm)	628.90M +13.6%
Net Income	-71.24M
EPS	-0.62
Shares Out	115.08M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,189,102
Open	27.72
Previous Close	27.04
Day's Range	26.58 - 27.72
52-Week Range	17.01 - 29.77
Beta	0.46
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About Hubei Goto Biopharm

Hubei Goto Biopharm Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of steroid drug raw materials in China and internationally. It offers starting materials, intermediates, and other pharmaceutical raw materials. The company was founded in 2006 and is based in Xiangyang, China.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 817
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300966

Financial Performance

In 2025, Hubei Goto Biopharm's revenue was 606.18 million, an increase of 12.97% compared to the previous year's 536.60 million. Losses were -73.36 million, 165.9% more than in 2024.